Part 1: The Biological Thesis of Aging

  1. On Evolutionary Trade-offs: "Large dogs die younger because we bred them for size, inadvertently selecting for high levels of IGF-1, a growth hormone that accelerates aging." — Source: Loyal Blog
  2. On Aging as a Driver: "Aging is the single greatest risk factor for almost every chronic disease; by targeting the underlying biology of aging, we can delay multiple diseases at once." — Source: The Upstarts Podcast
  3. On Dog-to-Human Translation: "Dogs are the best model for human aging because they live in our environment, share our lifestyle, and develop the same age-related diseases we do." — Source: Nature Biotech Interview
  4. On Preventative Medicine: "The goal isn't to fix what's broken, but to maintain the metabolic health of a senior dog so it never breaks in the first place." — Source: Vet Candy
  5. On Metabolic Mimicry: "One of our leads mimics the life-extending effects of caloric restriction by shifting a dog's metabolism into a 'fitness' state." — Source: Forbes
  6. On Healthspan vs. Lifespan: "Longevity isn't just about more years; it's about more healthy years where the dog is active, cognitive, and mobile." — Source: Longevity Technology
  7. On Biological Specificity: "You cannot just give a 'longevity pill'; you have to target specific pathways like the IGF-1 axis in large breeds where the biology is clear." — Source: Talking Biotech Podcast
  8. On Cognitive Decline: "Brain health is a core pillar of longevity; preventing neurodegeneration in senior dogs is as critical as physical mobility." — Source: Loyal Senior Dog Science
  9. On the Cellular Level: "Aging is a systemic failure of cellular maintenance; we are building tools to boost that maintenance before the failure occurs." — Source: She Leads Podcast
  10. On Environmental Factors: "Because dogs share our beds and our air, they are a 'canary in the coal mine' for how our shared environment affects the rate of aging." — Source: The Deep End

Part 2: Strategic Biotech Innovation & Regulatory Navigation

  1. On Regulatory Precedent: "We received the first-ever FDA acceptance for a drug intended to extend lifespan—this validates aging as a treatable condition." — Source: Loyal News
  2. On the 'Dog First' Strategy: "Developing longevity drugs for dogs is faster and cheaper than humans, allowing us to prove the science in 5 years rather than 50." — Source: Bloomberg
  3. On Milestone-Based Fundraising: "Every dollar we raise is tied to an increased probability of unlocking the market through a specific regulatory or scientific milestone." — Source: First Round Review
  4. On Market Risk vs. Scientific Risk: "In biotech, the risk isn't 'will people want this'—it's 'will it work and is it safe?' The market is guaranteed if the science is right." — Source: How to Build a Biotech
  5. On Regulatory 'Trauma': "The human regulatory path for longevity is filled with trauma and expense; the veterinary path is a clean, logical way to build the same thesis." — Source: Forbes 30 Under 30
  6. On Investor Incentives: "You have to find investors who aren't just looking for a 10x return but are mission-aligned with the radical extension of health." — Source: Foundersuite
  7. On Operations as Strategy: "The reason we don't have aging drugs isn't because the biology is unknown; it’s because the logistics of human trials are nearly impossible." — Source: Celine’s Blog
  8. On the Veterinary Advantage: "Vets see the end results of aging every day; they are our most important partners in validating that these drugs improve quality of life." — Source: Apple Podcasts - Science & Business of Longevity
  9. On Clinical Excellence: "A successful clinical trial in dogs requires the same rigor as human trials—placebo controls, double-blinding, and hard endpoints." — Source: Loyal Science Thesis
  10. On Building the Category: "We aren't just building a company; we are building the regulatory category for 'longevity drugs' from scratch." — Source: The Times Tech Podcast

Part 3: The Philosophy of Healthspan and Autonomy

  1. On the Definition of Free Will: "I became obsessed with aging when I realized that neurodegeneration and disease are the ultimate thieves of free will." — Source: The Upstarts Podcast
  2. On Preventative Ethics: "Is it ethical to wait for a dog to get sick before we treat them, if we know they are aging every single day?" — Source: Lady Scientist Podcast
  3. On Life’s Finiteness: "The goal isn't immortality; it’s about ensuring the time we do have is spent in full health and agency." — Source: Celine’s Twitter/X
  4. On Health Economics: "Curative therapeutics are economically superior to chronic management, yet our systems are incentivized for the latter." — Source: Oxford Thesis Background
  5. On the Mission-Driven Life: "Doing something that has never been done before is the only way to significantly move the needle for society." — Source: She Leads Podcast
  6. On Existential Urgency: "The realization that my parents and I are aging was the breakdown that became the breakthrough for my career." — Source: The Deep End
  7. On the Value of Pets: "Dogs are our closest companions; helping them live longer is the most empathetic way to introduce longevity to the world." — Source: Medium - Loyal Intro
  8. On Skeptical Optimism: "You must be a 'skeptical optimist'—deeply critical of the science but unshakably positive about the potential outcome." — Source: How to Build a Biotech
  9. On Scientific Honesty: "We must be honest about what we don't know; over-promising on 'immortality' hurts the credibility of serious longevity science." — Source: Longevity Technology
  10. On Agency over Biology: "We have the technology to not be victims of our evolutionary programming; aging is a problem that can be solved." — Source: Celine’s Blog

Part 4: Lessons on High-Impact Entrepreneurship

  1. On Naivety as a Superpower: "Being naive allowed me to ask 'why not?' about the FDA path when everyone else said it was impossible." — Source: The Upstarts Podcast
  2. On First Principles Thinking: "Don't look at how other biotech companies were built; look at the fundamental constraints of your specific mission." — Source: She Leads Podcast
  3. On Hiring Better Talent: "My best hires are the people who constantly tell me I’m wrong and show me a better way to execute." — Source: Foundersuite Interview
  4. On Opportunity at the Intersection: "The biggest breakthroughs happen at the intersection of fields, like combining health economics with nanobiotechnology." — Source: Medium - Celine Halioua
  5. On Building Important Things: "Don't build boring shit; the world has enough apps. Build things that fundamentally improve the human (or canine) condition." — Source: Foundersuite
  6. On Writing to Learn: "I write to synthesize my thoughts; if you can't explain your biotech thesis in a blog post, you don't understand it yet." — Source: Celine’s Blog
  7. On Moving Fast in Deep Tech: "Deep tech doesn't have to be slow; you just need to be more disciplined about your milestones and capital." — Source: First Round Review
  8. On the Founder’s Role: "A CEO’s job is to ensure the company doesn't run out of money and to hire people who are smarter than themselves." — Source: She Leads Podcast
  9. On the VC to Founder Transition: "Being a VC taught me what a good business looks like; being a founder is teaching me how hard it is to actually build one." — Source: The Deep End
  10. On Discipline: "Longevity is a long game; you need the discipline to stick with a scientific thesis for a decade or more." — Source: Lady Scientist Podcast

Part 5: Socializing the Future of Longevity

  1. On the 'Immortality' Branding Trap: "Stop calling it 'anti-aging' or 'immortality'; it makes the science sound like science fiction and scares people off." — Source: Celine’s Twitter/X
  2. On Making the Thesis 'Warm': "Dogs make the longevity conversation warm and accessible; it’s easier to talk about helping your Golden Retriever than living forever yourself." — Source: The Times Tech Podcast
  3. On Public Trust: "Biotech must be transparent; building trust with the public is as important as getting the FDA approval." — Source: Loyal Blog
  4. On the Longevity Bridge: "If we can prove longevity drugs work in dogs, the societal demand for the human version will become an unstoppable force." — Source: Bloomberg
  5. On the Future of Aging: "In twenty years, taking a longevity pill will be as normal as taking a daily multivitamin." — Source: Longevity Technology
  6. On Democratizing Longevity: "Longevity shouldn't just be for the elite; our goal at Loyal is to make these drugs affordable and accessible to every pet owner." — Source: Vet Candy
  7. On Changing the Narrative: "We need to move from 'fighting death' to 'optimizing life'; the narrative change is a prerequisite for the scientific change." — Source: The Deep End
  8. On Global Health Impact: "By delaying aging, we can reduce the global burden of disease more than any other single medical intervention." — Source: She Leads Podcast
  9. On the Intersection of Love and Science: "People love their dogs more than almost anything; that love is a powerful catalyst for scientific progress." — Source: Medium - Loyal Intro
  10. On the Ultimate Goal: "My core goal in life is to get the first aging drug approved, regardless of the species—once that door is open, it never closes." — Source: Forbes